AZ HB2166

Requires health care insurers and pharmacy benefits managers to include cost-sharing amounts paid by enrollees or third parties toward out-of-pocket maximums, deductibles, copayments, coinsurance, and other cost-sharing requirements for prescription drugs without generic equivalents.

Requires inclusion of cost-sharing for drugs with generic equivalents if the enrollee obtained access through prior authorization, step therapy protocols, or the insurer's exceptions and appeals process.

Defines "generic equivalent" as a drug with identical active chemical ingredients in the same dosage form meeting United States pharmacopeia standards that provides comparable therapeutic effects, excluding drugs with FDA-listed unresolved bioequivalence concerns.

Effective date of December 31, 2019.